Trial Profile

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 25 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Dec 2025 According to an Immunome media release, company announced it will host a conference call and webcast on Monday, December 15, 2025, at 8:30 a.m. ET to present topline results from the global pivotal phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors.
15 Dec 2025 Primary endpoint has been met. (Progression free survival)
15 Dec 2025 According to an Immunome media release, the company plans to share additional data from the RINGSIDE trial at an upcoming major medical conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com